PeterHaraldLangsjoenMDFACC

PubMed

• 78 citations
  Statins stimulate atherosclerosis and heart failure: pharmacological mechanisms
  Harumi Okuyama, Peter H Langsjoen, Tomohito Hamazaki, Yoichi Ogushi, Rokuro Hama
  Expert Review of Clinical Pharmacology. 2015-02-19
• 88 citations
  Overview of the use of CoQ10 in cardiovascular disease.
  Peter H. Langsjoen, Alena M. Langsjoen
  Biofactors. 1999-01-01
• 182 citations
  Lack of an association or an inverse association between low-density-lipoprotein cholesterol and mortality in the elderly: a systematic review
  Uffe Ravnskov, David M. Diamond, Rokura Hama, Tomohito Hamazaki, Björn Hammarskjöld
  BMJ Open. 2016-06-01

Journal Articles

• Statins stimulate atherosclerosis and heart failure: pharmacological mechanisms.  
  Okuyama H, Langsjoen PH, Hamazaki T, Ogushi Y, Hama R, Kobayashi T, Uchino H., Expert Rev Clin Pharmacol. 2015 Mar;8(2):189-99., 3/8/2015
• Comparison study of plasma coenzyme Q10 levels in healthy subjects supplemented with ubiquinol versus ubiquinone.  
  1. Langsjoen, P.H. and Langsjoen, A.M., Clinical Pharmacology in Drug Development, 2014 (Jan/Feb);3(1):13-17., 2/2014
• Comparison study of plasma coenzyme Q10 levels in healthy subjects supplemented with ubiquinol versus ubiquinone  
  Langsjoen, P.H. and Langsjoen, A.M., Clinical Pharmacology in Drug Development, 1/1/2014
• Coenzyme Q10 and statins: biochemical and clinical implications.  
  Littarru G.P., Langsjoen P., Mitochondrion, 2007
• Role of concomitant coenzyme Q10 with statins for patients with hyperlipidemia  
  Langsjoen P.H., Littarru. g.P., Silver, M.A., Current Topics in Nutriceutical Research, 1/1/2005
• The clinical use of HMg CoA-reductase inhibitors and the associated depletion of coenzyme Q10 A review of animal and human publications  
  Langsjoen P.H, Langsjoen, A.M., BioFactors, 1/1/2003
• "Comment"  
  Langsjoen P.H., J Am Coll Cardiol, 3/1/2000
• Review of Coenzyme Q10 in Cardiovascular Disease with Emphasis on Heart Failure and Ischemia Reperfusion  
  Langsjoen P.H., Langsjoen A.M., Asia Pacific Heart J, 1/1/1998
• Lovastatin decreases coenzyme Q levels in humans  
  Folkers K, Langsjoen P, Willis R, Richardson P, Xia LJ, Ye CQ, Tamagawa H, Proc Natl Acad Sci USA, 11/1/1990
• Biomedical and Clinical Aspects of Coenzyme Q  
  Langsjoen P.H., Langsjoen P.H., Morishita M., Muratzu K., Lyson K., Folkers K., 1/1/1986
• Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q10  
  Langsjoen PH, Vadhanavikit S, Folkers K, Proc Natl Acad Sci U S A, 6/1/1985
• Join now to see all

Books/Book Chapters

• Anti-Aging Medical Therapeutics 
  Chapter: The Aging Heart: Reversal of Diastolic Dysfunction Through the Use of Oral CoQ10 in the Elderly. 
  Page 113 - 120Langsjoen P.H., Langsjoen A., Willis A, Folkers, K.Editors: R.M.Klatz and R. goldman.Health Quest Publications1997
• Biomedical and Clinical Aspects of Coenzyme Q 
  Chapter: Treatment of patients with human immunodeficiency virus infection with coenzyme Q10. 
  Page 409 - 415Langsjoen P.H., Langsjoen P.H., Folkers K., Richardson P.Editors: Folkers K., Littarru g.P., and Yamagami, T..1991

Abstracts/Posters

• Comparison study of plasma coenzyme Q10 levels in healthy subjects supplemented with ubiquinol versus ubiquinone.
  Langsjoen, P.H. and Langsjoen, A.M., Clinical Pharmacology in Drug Development, 1/1/2014
• Statin contraindicated in heart failure.
  Vos E, Mascitelli L, Langsjoen PH, Angiology, 10/1/2008
• Supplemental ubiquinol in patients with advanced congestive heart failure.
  Langsjoen PH, Langsjoen AM, Biofactors, East Texas Medical Center and Trinity Mother Francis Hospital, TX, 1/1/2008
• Treatment of statin adverse effects with supplemental Coenzyme Q10 and statin drug discontinuation.
  Langsjoen PH, Langsjoen JO, Langsjoen AM, Lucas LA, BioFactors, East Texas Medical Center and Trinity Mother Francis Hospital, Tyler, TX, 1/1/2005
• Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction.
  Silver MA, Langsjoen PH, Szabo S, Patil H, Zelinger A, Am J Cardiol, Heart Failure Institute, Department of Medicine, Advocate Christ Medical Center, University of Illin, 11/15/2004
• Statin cardiomyopathy? A potential role for Co-Enzyme Q10 therapy for statin-induced changes in diastolic LV performance: description of a clinical protocol.
  Silver MA, Langsjoen PH, Szabo S, Patil H, Zelinger A, Biofactors, Heart Failure Institute, Division of Cardiology, Department of Medicine, Advocate Christ Medical Cen, 1/1/2003
• The clinical use of HMg CoA-reductase inhibitors and the associated depletion of coenzyme Q10. A review of animal and human publications.
  Langsjoen PH, Langsjoen AM, BioFactors, East Texas Medical Center and Trinity Mother Francis Health System, Tyler, TX, 1/1/2003
• Overview of the use of CoQ10 in cardiovascular disease.
  Langsjoen PH, Langsjoen AM, BioFactors, 1/1/1999
• Review of Coenzyme Q10 in Cardiovascular Disease with Emphasis on Heart Failure and Ischemia Reperfusion.
  Langsjoen P.H., Langsjoen A.M., Asia Pacific Heart J, 1/1/1998
• Treatment of hypertrophic cardiomyopathy with coenzyme Q10.
  Langsjoen PH, Langsjoen A, Willis R, Folkers K, Mol Aspects Med, Langsjoen Clinic, Tyler, TX, 1/1/1997
• Treatment of essential hypertension with coenzyme Q10.
  Langsjoen P, Langsjoen P, Willis R, Folkers K, Mol Aspects Med, Institute for Biomedical Research, University of Texas at Austin, 1/1/1994
• Usefulness of coenzyme Q10 in clinical cardiology: a long-term study.
  Langsjoen H, Langsjoen P, Langsjoen P, Willis R, Folkers K, Mol Aspects Med, University of Texas Medical Branch, galveston, TX, 1/1/1994
• Isolated diastolic dysfunction of the myocardium and its response to CoQ10 treatment.
  Langsjoen PH, Langsjoen PH, Folkers K, Clin Investig, 1/1/1993
• Therapy with coenzyme Q10 of patients in heart failure who are eligible or ineligible for a transplant.
  Folkers K, Langsjoen P, Langsjoen PH, Biochem Biophys Res Commun, Institute for Biomedical Research, University of Texas, Austin, 1/1/1992
• Coenzyme Q10 increases T4/T8 ratios of lymphocytes in ordinary subjects and relevance to patients having the AIDS related complex.
  Folkers K, Hanioka T, Xia LJ, McRee JT Jr, Langsjoen P, Biochem Biophys Res Commun, Institute for Biomedical Research, University of Texas, Austin, 1/1/1991
• Treatment of patients with human immunodeficiency virus infection with coenzyme Q10.
  Langsjoen P.H., Langsjoen P.H., Folkers K., Richardson P., Biomedical and Clinical Aspects of Coenzyme Q, 1/1/1991
• Lovastatin decreases coenzyme Q levels in humans.
  Folkers K, Langsjoen P, Willis R, Richardson P, Xia LJ, Ye CQ, Tamagawa H, Proc Natl Acad Sci U S A, University of Texas, Austin, 1/1/1990
• Long-term efficacy and safety of coenzyme Q10 therapy for idiopathic dilated cardiomyopathy.
  Langsjoen PH, Langsjoen PH, Folkers K, Am J Cardiol, Scott and White Clinic, Temple, TX, 1/1/1990
• A six-year clinical study of therapy of cardiomyopathy with coenzyme Q10.
  Langsjoen PH, Langsjoen PH, Folkers K, Int J Tissue React, Department of Medicine, Scott & White Clinic, Temple, TX, 1/1/1990
• Pronounced increase of survival of patients with cardiomyopathy when treated with coenzyme Q10 and conventional therapy.
  Langsjoen PH, Folkers K, Lyson K, Muratsu K, Lyson T, Langsjoen P, Int J Tissue React, Department of Medicine, Scott and White Clinic, Temple, TX, 1/1/1990
• Effective and safe therapy with coenzyme Q10 for cardiomyopathy.
  Langsjoen PH, Folkers K, Lyson K, Muratsu K, Lyson T, Langsjoen P, Klin Wochenschr, Department of Medicine, Scott and White Clinic, Temple, TX, 1/1/1988
• Biochemical deficiencies of coenzyme Q10 in HIV-infection and exploratory treatment.
  Folkers K, Langsjoen P, Nara Y, Muratsu K, Komorowski J, Richardson PC, Smith TH, Biochem Biophys Res Commun, Institute for Biomedical Research, University of Texas, Austin, 1/1/1988
• The long-term value of Coenzyme Q10 in patients with cardiomyopathy.
  Langsjoen P.H., Langsjoen P.H., Morishita M., Muratzu K., Lyson K., Folkers K., Biomedical and Clinical Aspects of Coenzyme Q, 1/1/1986
• Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q10.
  Langsjoen PH, Vadhanavikit S, Folkers K, Proc Natl Acad Sci U S A, 6/1/1985
• Coenzyme Q10 and statins: biochemical and clinical implications.
  Littarru GP, Langsjoen P, Institute of Biochemistry, Polytechnic University of the Marche, Via Ranieri, Ancona, Italy
• Join now to see all

Other

• Alleviating Congestive Heart Failure with Coenzyme Q10. 
  Langsjoen, P.H., Life Extension Magazine
  2/1/2008